MORE►
taysha gene therapies
[Source image: istockphoto]
Taysha Gene Therapies Raises $150M for Its Rare Disease Drug Pipeline
by Lance Murray | Aug 16, 2023
Led by new investor RA Capital Management, the new funding is expected to extend Taysha's cash runway into the third quarter of 2025, and aid in its development of a gene therapy treatment targeting Rett Syndrome, a neurological disorder that occurs primarily in girls.
by Nicole Ward, DRC Data Journalist |
Jun 8, 2023
Elina Lavit, originally from the Soviet Union, charted a new course in 2021. Swapping San Francisco for Dallas, she's now steering business development at OncoNano Medicine, a North Texas biotech that aims to revolutionize cancer treatment.
MORE►
by Dallas Innovates | Staff Report |
Apr 4, 2023
Dr. Zajicek and three other local biotech leaders—Sulagna Bhattacharya, CEO of Nanoscope Therapeutics; Gabby Everett, director of business operations and strategy at BioLabs Pegasus Park; and R.A. Session II, founder of Taysha Gene Therapies—discussed Dallas' biotech boom on a panel hosted by D CEO Healthcare.
MORE►
by Dallas Innovates | Staff Report |
Mar 1, 2023
Dallas-Fort Worth is well known for its tech expertise. Now it being recognized as the place where technology meets life science—a convergence that’s driving rapid growth in the biotech ecosystem....
MORE►
[Source image: istockphoto]
Taysha Gene Therapies Replaces CEO, Appoints R&D Chief
by Quincy Preston | Dec 19, 2022
Dallas-based Taysha Gene Therapies is starting a new chapter in its fight to tackle devastating neurological conditions with changes in its top executive leadership.
Late Friday, the publicly traded biotech announced that Sean P. Nolan, the current chair of the board of directors and an experienced biopharmaceutical industry leader, is the company’s new CEO....
MORE►
by Lance Murray |
Nov 3, 2022
Now in its fourth year, the program from Dallas Innovates and D CEO honors 68 disruptors and trailblazers driving a new vision for innovation in North Texas.
Finalists will be recognized in the January/February issue of D CEO magazine and online at DallasInnovates.com. Winners will be revealed at an exclusive awards event in January.
MORE►
by Kevin Cummings |
Oct 28, 2022
In this week’s North Texas deal flow, you’ll also find news about Taysha Gene Therapies landing a $50M investment; music tech startup MAX’s Series B raise; Dallas Venture Capital’s latest investment; Tyler Technologies’ $68M acquisition of Rapid Financial Solutions; NaturalShrimp hitting the Nasdaq Capital Market; and more.
MORE►
![R.A. Session II, president, CEO, and founder of Taysha Gene Therapies [Background image: Olena Yepifanova via iStock]](https://s24806.pcdn.co/wp-content/uploads/2020/04/TayshaGene-Session-970-1-360x203.jpg)
by Kevin Cummings |
Oct 25, 2022
The investment by Tokyo-based Astellas Pharma gives it a 15% stake in Taysha and positions it to potentially purchase the company, according to the Dallas Morning News. The Dallas-based biotech firm's pipeline includes the "first-and-only" gene therapy in clinical development for Rett syndrome and a Phase 1/2 development of a treatment for an inherited nervous system disorder that's awaiting regulatory feedback.
“We believe this investment not only further validates the potential of our technology platform, but also reinforces the therapeutic and market opportunity of our two lead clinical assets,” Founder and CEO R.A. Sessions II says.
“We believe this investment not only further validates the potential of our technology platform, but also reinforces the therapeutic and market opportunity of our two lead clinical assets,” Founder and CEO R.A. Sessions II says.
MORE►
[Image: mel-nik/istockphoto]
Follow the Money: D.R. Horton Acquires Public Water Resources Firm, Critical Start Raises $215M, Fort Worth Biotech VC Raises New Funds, and More
by Kevin Cummings | Apr 15, 2022
What companies are finding funding or having a big exit? From startup investments to grants and acquisitions, Dallas Innovates tracks what’s happening in North Texas money.
MORE►
by David Kirkpatrick |
Jan 25, 2022
The accelerator will move this summer from its downtown Dallas location to 6,000 square feet of collaborative and flexible office space in Pegasus Park's 18-story tower.
Just weeks ago, Pegasus Park landed one of its biggest tenants to date: UT Southwestern‘s Office for Technology Development and other UTSW entities will be leasing six floors in the tower.
MORE►
by Dallas Innovates | Staff Report |
Oct 26, 2021
Now in its third year, the program from Dallas Innovates and D CEO honors 78 disruptors and trailblazers driving a new vision for innovation in North Texas.
MORE►
by Alex Edwards |
Apr 12, 2021
Taysha Gene Therapies, which rocketed from a UTSW spinout to a $157 million IPO in under six months last year, has gone global with rights to TSHA-120, a promising AAV9 clinical-stage gene therapy.
It's a historic announcement. There are no current treatments for giant axonal neuropathy, or GAN, a severe, progressive disease that affects the central and peripheral nervous systems. TSHA-120 is the first-ever successful in-human intrathecal (spinal) gene transfer.
It's a historic announcement. There are no current treatments for giant axonal neuropathy, or GAN, a severe, progressive disease that affects the central and peripheral nervous systems. TSHA-120 is the first-ever successful in-human intrathecal (spinal) gene transfer.
MORE►
Claire Aldridge [Photo: Bret Redman; Photo art: Michael Samples]
Through Roles at UTSW and Pegasus Park, Claire Aldridge Leads Efforts to Make DFW a Key Center for Healthcare Innovation
by Quincy Preston and Sandra Engelland | Feb 24, 2021
With an entrepreneurial mindset, Aldridge turns scientific discoveries into real-world solutions. Here's how Aldridge is playing a large role in making Dallas a destination for biotech and life sciences.
MORE►
by Alex Edwards |
Jan 13, 2021
The expanded alliance between Taysha and UTSW, which dates back to when Taysha emerged from stealth in April 2020, will support the discovery of novel gene therapy candidates and technologies in new disease areas.
MORE►
by Quincy Preston and Alex Edwards |
Aug 5, 2020
Taysha Gene Therapies, which was been operating in stealth with UT Southwestern until this April, plans to use the financing to advance its initial cohort of lead programs into its clinic. By the end of 2021, Taysha expects to file four Investigational New Drug applications.
MORE►
